Price
$117.38
Increased by +1.91%
Dollar volume (20D)
142.64 M
ADR%
5.20
Earnings report date
Nov 11, 2025
Shares float
32.96 M
Shares short
7.84 M [23.80%]
Shares outstanding
34.09 M
Market cap
3.93 B
Beta
2.08
Price/earnings
57.88
20D range
111.30 133.54
50D range
98.89 141.90
200D range
55.00 145.50

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.

The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.

The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Reported date EPSChange YoY EstimateSurprise
Jul 29, 25 0.92
Increased by +162.86%
0.45
Increased by +106.60%
Apr 28, 25 0.70
Increased by +100.00%
0.24
Increased by +190.10%
Feb 24, 25 0.19
Increased by +58.33%
0.22
Decreased by -13.64%
Oct 28, 24 0.12
Increased by +115.38%
0.29
Decreased by -58.62%
Jul 31, 24 0.35
Increased by +1.27 K%
0.21
Increased by +66.67%
Apr 30, 24 0.35
Increased by +537.50%
-0.04
Increased by +975.00%
Feb 26, 24 0.12
Increased by +157.14%
-0.03
Increased by +500.00%
Nov 6, 23 -0.78
Decreased by -212.00%
-0.16
Decreased by -387.50%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 157.37 M
Increased by +37.68%
34.91 M
Increased by +186.26%
Increased by +22.18%
Increased by +107.93%
Mar 31, 25 143.54 M
Increased by +48.21%
25.68 M
Increased by +110.56%
Increased by +17.89%
Increased by +42.07%
Dec 31, 24 121.62 M
Increased by +49.83%
6.86 M
Increased by +70.11%
Increased by +5.64%
Increased by +13.53%
Sep 30, 24 108.76 M
Increased by +63.72%
4.22 M
Increased by +116.58%
Increased by +3.88%
Increased by +110.13%
Jun 30, 24 114.31 M
Increased by +117.87%
12.19 M
Increased by +1.32 K%
Increased by +10.67%
Increased by +659.13%
Mar 31, 24 96.85 M
Increased by +133.07%
12.20 M
Increased by +562.71%
Increased by +12.59%
Increased by +298.53%
Dec 31, 23 81.17 M
Increased by +158.72%
4.03 M
Increased by +159.99%
Increased by +4.97%
Increased by +123.19%
Sep 30, 23 66.43 M
Increased by +158.65%
-25.42 M
Decreased by -242.34%
Decreased by -38.27%
Decreased by -32.35%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY